Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary
Peter Batar, Hussain Alizadeh, Gyorgy Rokszin, Zsolt Abonyi-Toth, Judit Demeter
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsChronic Myeloid Leukemia Treatments
In the published article, there was an error in the Funding statement. It originally stated:
“The authors declare that this study received funding from Pfizer. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.”
The Funding statement has now been removed.
In the published article, there was an error in the Conflict of interest Statement. It originally stated:
“Authors GR and ZA-T were employed by RxTarget Ltd.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”
The correct Conflict of interest statement appears below.
“GR and ZA-T are employees of RxTarget Ltd., which was a paid contractor to Pfizer in connection with the development of this manuscript and was responsible for data curation and statistical analysis. This study was sponsored by Pfizer. Medical writing support was provided by Zsófia Barcza at Syntesia Medical Communications Ltd. and was funded by Pfizer. The funder had the following involvement in the study: administrative support and review regarding study design, statistical analysis, and manuscript development.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.